The combination therapy of SGLT2 inhibitors and ARBs/ACE inhibitors is expected to have greater renoprotective effects compared with administration of either drug alone because of synergistic effects in patients with DN [33]. This evidence concerns the gene ACE and liver dysplastic nodule.